Syntara (ASX:SNT) Earnings Call Presentation

Company Overview - Syntara is an Australian-founded clinical stage drug developer focused on first-in-class and best-in-class drugs backed by a long-life patent portfolio[8] - The company is funded into 2027 with near-term data expected to drive value over the next 12-18 months[8] - Syntara has secured A$8.5 million in non-dilutive grant funding in the last 3 years[9] - As of September 5, 2025, Syntara's share price was A$0.025, resulting in a market capitalization of A$40.8 million[12] Amsulostat (SNT-5505) in Myelofibrosis (MF) - Interim Phase 2 data reported in June 2025 showed a 42% reduction of bone marrow collagen fibrosis grade in evaluable myelofibrosis patients after 6 months of monotherapy[21] - 73% (8/11) of patients achieved TSS50 (Total Symptom Score reduction of 50%) at Week 24 or beyond in the Phase 2a MF combination study[32] - 44% (4/9) of patients achieved SVR25 (Spleen Volume Reduction of 25%) at Week 24 or beyond in the Phase 2a MF combination study[35] - The current standard of care for myelofibrosis has a revenue of approximately US$1.9 billion per annum[31] SNT-9465 in Skin Scarring - The total scar treatment market in 2019 exceeded US$19 billion, with the keloid and hypertrophic scar segment accounting for approximately US$3.5 billion[51] - SNT-9465 is a next-generation topical inhibitor with optimized tolerability and efficacy, currently undergoing Phase 1a/b trials with results expected in H1 2026[61, 62]